|
1
|
Kong Z, Xie D, Boike T, Raghavan P, Burma
S, Chen DJ, Habib AA, Chakraborty A, Hsieh JT and Saha D:
Downregulation of human DAB2IP gene expression in prostate cancer
cells results in resistance to ionizing radiation. Cancer Res.
70:2829–2839. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanks GE, Pajak TF, Porter A, et al: Phase
III trial of long-term adjuvant androgen deprivation after
neoadjuvant hormonal cytoreduction and radiotherapy in locally
advanced carcinoma of the prostate: The radiation therapy oncology
group protocol 92–02. J Clin Oncol. 21:3972–3978. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roach M III: Radiotherapy plus adjuvant
goserelin improves survival in men with poor prognosis prostate
cancer. Cancer Treat Rev. 31:582–586. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xie D, Gore C, Zhou J, Pong RC, Zhang H,
Yu L, Vessella RL, Min W and Hsieh JT: DAB2IP coordinates both
PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc
Natl Acad Sci USA. 106:19878–19883. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen H, Toyooka S, Gazdar AF and Hsieh JT:
Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in
prostate cancer cell lines. J Biol Chem. 278:3121–30. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu K, Liu J, Tseng SF, et al: The role of
DAB2IP in androgen receptor activation during prostate cancer
progression. Oncogene. 33:1954–1963. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xie D, Gore C, Liu J, et al: Role of
DAB2IP in modulating epithelial-to-mesenchymal transition and
prostate cancer metastasis. Proc Natl Acad Sci USA. 107:2485–2490.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Min J, Zaslavsky A, Fedele G, et al: An
oncogene-tumor suppressor cascade drives metastatic prostate cancer
by coordinately activating Ras and nuclear factor-kappaB. Nat Med.
16:286–294. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Z, Tseng CP, Pong RC, et al: The
mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate
cancer. Characterization of a novel GTPase-activating protein
associated with N-terminal domain of DOC-2/DAB2. J Biol Chem.
277:12622–12631. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu K, Xie D, Zou Y, et al: The mechanism
of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer
Res. 19:4740–4749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kong Z, Raghavan P, Xie D, et al:
Epothilone B confers radiation dose enhancement in DAB2IP gene
knock-down radioresistant prostate cancer cells. Int J Radiat Oncol
Biol Phys. 78:1210–1218. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu L, Tumati V, Tseng SF, et al: DAB2IP
regulates autophagy in prostate cancer in response to combined
treatment of radiation and a DNA-PKcs inhibitor. Neoplasia (New
York, NY). 14:1203–1212. 2012. View Article : Google Scholar
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tutar L, Tutar E and Tutar Y: MicroRNAs
and cancer; an overview. Curr Pharm Biotechnol. 15:430–437. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Walter BA, Valera VA, Pinto PA and Merino
MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer.
4:350–357. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leung CM, Li SC, Chen TW, et al:
Comprehensive microRNA profiling of prostate cancer cells after
ionizing radiation treatment. Oncol Rep. 31:1067–1078.
2014.PubMed/NCBI
|
|
18
|
Liu K, Huang J, Xie M, et al: MIR34A
regulates autophagy and apoptosis by targeting HMGB1 in the
retinoblastoma cell. Autophagy. 10:442–452. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu B, Che W, Xue J, et al: SIRT4 prevents
hypoxia-induced apoptosis in H9c2 cardiomyoblast cells. Cell
Physiol Biochem. 32:655–662. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tanida I, Ueno T and Kominami E: LC3
conjugation system in mammalian autophagy. Int J Biochem Cell Biol.
36:2503–2518. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sou YS, Tanida I, Komatsu M, Ueno T and
Kominami E: Phosphatidylserine in addition to
phosphatidylethanolamine is an in vitro target of the mammalian
Atg8 modifiers, LC3, GABARAP and GATE-16. J Biol Chem.
281:3017–3024. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rouschop KM, van den Beucken T, Dubois L,
et al: The unfolded protein response protects human tumor cells
during hypoxia through regulation of the autophagy genes MAP1LC3B
and ATG5. J Clin Invest. 120:127–141. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jung CH, Kim H, Ahn J, Jung SK, Um MY, Son
KH, Kim TW and Ha TY: Anthricin isolated from Anthriscus
sylvestris (L.) Hoffm. Inhibits the growth of breast cancer cells
by inhibiting Akt/mTOR signaling and its apoptotic effects are
enhanced by autophagy inhibition. Evid Based Complement
Alternat Med. 2013:3852192013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zeng X and Kinsella TJ: Mammalian target
of rapamycin and S6 kinase 1 positively regulate
6-thioguanine-induced autophagy. Cancer Res. 68:2384–2390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scott RC, Schuldiner O and Neufeld TP:
Role and regulation of starvation-induced autophagy in the
Drosophila fat body. Dev Cell. 7:167–178. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Klionsky DJ, Meijer AJ and Codogno P:
Autophagy and p70S6 kinase. Autophagy. 1:59–60. 2005.discussion
60-1. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe
TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al:
Genomic profiling of microRNA and messenger RNA reveals deregulated
microRNA expression in prostate cancer. Cancer Res. 68:6162–6170.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Paller CJ, Antonarakis ES, Eisenberger MA
and Carducci MA: Management of patients with biochemical recurrence
after local therapy for prostate cancer. Hematol Oncol Clin North
Am. 27:1205–1219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Orth M, Lauber K, Niyazi M, Friedl AA, Li
M, Maihöfer C, Schüttrumpf L, Ernst A, Niemöller OM and Belka C:
Current concepts in clinical radiation oncology. Radiat Environ
Biophys. 53:1–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kaliberov SA and Buchsbaum DJ: Chapter
seven - Cancer treatment with gene therapy and radiation therapy.
Adv Cancer Res. 115:221–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huber TB, Edelstein CL, Hartleben B, Inoki
K, Jiang M, Koya D, Kume S, Lieberthal W, Pallet N, Quiroga A, et
al: Emerging role of autophagy in kidney function, diseases and
aging. Autophagy. 8:1009–1031. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hale AN, Ledbetter DJ, Gawriluk TR and
Rucker EB: 3rd: Autophagy: Regulation and role in development.
Autophagy. 9:951–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Massoner P, Thomm T, Mack B, Untergasser
G, Martowicz A, Bobowski K, Klocker H, Gires O and Puhr M: EpCAM is
overexpressed in local and metastatic prostate cancer, suppressed
by chemotherapy and modulated by MET-associated miRNA-200c/205. Br
J Cancer. 111:955–964. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schmukler E, Shai B, Ehrlich M and
Pinkas-Kramarski R: Neuregulin promotes incomplete autophagy of
prostate cancer cells that is independent of mTOR pathway
inhibition. PLoS One. 7:e368282012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livesey KM, Tang D, Zeh HJ and Lotze MT:
Autophagy inhibition in combination cancer treatment. Curr Opin
Investig Drugs. 10:1269–1279. 2009.PubMed/NCBI
|
|
38
|
Chen H, Tu SW and Hsieh JT:
Down-regulation of human DAB2IP gene expression mediated by
polycomb Ezh2 complex and histone deacetylase in prostate cancer. J
Biol Chem. 280:22437–22444. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qiang XF, Zhang ZW, Liu Q, Sun N, Pan LL,
Shen J, Li T, Yun C, Li H and Shi LH: miR-20a promotes prostate
cancer invasion and migration through targeting ABL2. J Cell
Biochem. 115:1269–1276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q,
Wei Q, Li X, Wang J and Zeng H: MicroRNA-494-3p targets CXCR4 to
suppress the proliferation, invasion and migration of prostate
cancer. Prostate. 74:756–767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kang S, Zhao Y, Hu K, Xu C, Wang L, Liu J,
Yao A, Zhang H and Cao F: miR-124 exhibits antiproliferative and
antiaggressive effects on prostate cancer cells through PACE4
pathway. Prostate. 74:1095–1106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Surviladze Z, Sterk RT, DeHaro SA and
Ozbun MA: Cellular entry of human papillomavirus type 16 involves
activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway
and inhibition of autophagy. J Virol. 87:2508–2517. 2013.
View Article : Google Scholar : PubMed/NCBI
|
